Table 1.
Sample characteristics of all COVID-19 patients with sickle cell disease (SCD) or sickle cell trait (SCT) based on aggregated data from the literature included in this review.
| SCD n = 2290 |
n | SCT n = 1937 |
n | |
|---|---|---|---|---|
| Demographics | ||||
| Age in years, median (IQR) | 25 (17–39) | 140 | 54 (40–61) | 24 |
| Female sex, n (%) | 1041 (56) | 1858 | 319 (54) | 591 |
| HbSS genotype, n (%) | 171 (62) | 278 | n/a | n/a |
| Comorbidities, n (%) | 1025 | 563 | ||
| Cardiovascular disease | 28 (3) | 38 (7) | ||
| Chronic kidney disease | 107 (10) | 67 (12) | ||
| Asthma or COPD | 113 (11) | 170 (30) | ||
| Diabetes | 50 (5) | 137 (23) | ||
| Heart failure | 46 (5) | 46 (8) | ||
| Hypertension | 149 (15) | 237 (42) | ||
| Liver disease | 31 (3) | 34 (6) | ||
| Stroke | 100 (10) | 15 (3) | ||
| Vitals, median (IQR) | ||||
| Oxygen saturation (%) | 95 (88–97) | 70 | 96 (91–98) | 16 |
| Body temperature (F) | 101.6 (100.4–102.3) | 44 | 100.3 (98.7–101.6) | 15 |
| Body mass index (kg/m2) | 28 (25–34) | 30 | 32 (27–35) | 18 |
| Laboratory Values, median (IQR) | ||||
| Lactate dehydrogenase (U/L) | 732 (495–917) | 47 | 392 (292–576) | 10 |
| Lymphocytes (x109/L) | 2.3 (1.2–4.4) | 70 | 0.9 (0.6–1.4) | 13 |
| Total bilirubin (mg/dL) | 2.7 (0.9–4.3) | 36 | 0.5 (0.4–1.1) | 11 |
| White blood cell count (x109/L) | 13 (8.3–18.2) | 75 | 8.8 (5–13.3) | 16 |
| Hemoglobin (g/dL) | 8.0 (6.7–9.6) | 100 | 11.4 (9.8–13) | 16 |
| C-reactive protein (mg/dL) | 6.3 (0.9–18.7) | 72 | 9.9 (2.2–20.5) | 10 |
| D-dimer (μg/mL) | 3.3 (0.8–7.7) | 50 | 1.3 (2.7–21.5) | 8 |
Abbreviations: COPD, chronic obstructive pulmonary disease; IQR, interquartile range.